Bank of New York Mellon Corp Boosts Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Bank of New York Mellon Corp grew its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 123,832 shares of the specialty pharmaceutical company's stock after acquiring an additional 4,404 shares during the quarter. Bank of New York Mellon Corp owned about 0.59% of ANI Pharmaceuticals worth $6,845,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. KBC Group NV increased its stake in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after acquiring an additional 579 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth $222,000. Hohimer Wealth Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth $264,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after acquiring an additional 412 shares during the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

ANI Pharmaceuticals Stock Performance

ANIP traded up $0.13 during trading on Tuesday, hitting $64.48. 9,167 shares of the stock were exchanged, compared to its average volume of 238,643. The firm has a market capitalization of $1.40 billion, a P/E ratio of -117.24 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81. The stock has a fifty day moving average price of $58.59 and a two-hundred day moving average price of $58.07. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $191,776 over the last quarter. Company insiders own 12.70% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ANIP shares. Guggenheim increased their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. HC Wainwright reiterated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday. Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price target for the company. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday. They set a "buy" rating and a $80.00 price target for the company. Finally, StockNews.com upgraded ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $79.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.